Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open, Dose-escalation, Multi-center, Phase 1/2a Trial to Evaluate the Safety, Tolerability and to Explore the Efficacy of PN-101 in Patients With Refractory Polymyositis or Dermatomyositis

NCT04976140 is registered in ClinicalTrials.gov with Paean Biotechnology Inc. as lead sponsor.

NCT NCT04976140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04976140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open, Dose-escalation, Multi-center, Phase 1/2a Trial to Evaluate the Safety, Tolerability and to Explore the Efficacy of PN-101 in Patients With Refractory Polymyositis or Dermatomyositis
Lead sponsor
Paean Biotechnology Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 15, 2021
Completion date
October 6, 2023
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, polymyositis